Immunome (IMNM) Free Cash Flow (2019 - 2026)

Immunome (IMNM) has 8 years of Free Cash Flow data on file, last reported at -$61.6 million in Q1 2026.

• Quarterly Free Cash Flow fell 8.67% year-over-year to -$61.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$205.5 million (down 26.15% YoY) and the FY2025 annual result came in at -$200.6 million, down 70.05% from the prior year.
• Free Cash Flow retreated to -$61.6 million in Q1 2026, from -$52.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $24.0 million in Q1 2023 to a low of -$61.6 million in Q1 2026.
• A 5-year average of -$24.5 million and a median of -$17.5 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow jumped 475.27% — and 2025, when it plunged 382.15%.
• Tracing IMNM's Free Cash Flow over 5 years: stood at -$6.8 million in 2022, then slumped by 159.3% to -$17.5 million in 2023, then tumbled by 146.55% to -$43.2 million in 2024, then declined by 20.3% to -$52.0 million in 2025, then retreated by 18.65% to -$61.6 million in 2026.
• The last three Free Cash Flow figures came in at -$61.6 million (Q1 2026), -$52.0 million (Q4 2025), and -$44.9 million (Q3 2025), per Business Quant data.